Identification of Phenotype and Evaluation of Therapeutic Drugs on Canine Lymphoma Cells
Date Issued
2014
Date
2014
Author(s)
Wu, Rui-Hong
Abstract
Canine lymphoma is the most common hematopoietic tumor affecting dog. The remission rate of canine lymphoma treated by available combination chemotherapy protocols is usually high (80%-90%). However, most dogs eventually succumb to drug-resistant recurrence, on average, 1 year after diagnosis. Since no more therapeutic option other than chemotherapy, canine lymphoma is simply classified as B cell or T cell type so far. Therefore, offering more therapeutic options for different types of canine lymphoma will be necessary. In this study, flow cytometry (CD3, CD4, CD5, CD8, CD21, CD34, CD45, CD56, and CD79αcy), immunocytochemistry (MUM-1, Bcl-6, Bcl-2, CD10 and KMO) and PCR/RT-PCR (p53, FLT3, NRAS and BRAF) were used to identify the phenotypes of canine lymphoma cell lines, CLBL-1 (B cell type), CLC (non-T non-B cell type) and UL-1 (T cell type). A G485A point mutation causing R162H mutation was found in p53 gene of UL-1 cells. In subsequent viability assay, small molecule inhibitor, kyneurenine 3-monooxygenase (KMO) inhibitor and novel alkylating agents, BO-1055, BO-1922, BO-2094 and BO-1978, significantly reduced proliferation of all cell lines. This revealed their therapeutic potential on canine lymphoma. Future studies will focus on analysis of drugs mechanism.
Subjects
犬淋巴瘤
表型分析
流式細胞技術
烷基化藥物
Kynurenine 3-monooxygenase (KMO)
dovitinib
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-103-R01629004-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):140bdf1f9a288465bde8f1b76d4d6e1e